Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Viking Therapeutics, Inc. (VKTX)

4.01   -0.08 (-1.96%) 11-25 13:00
Open: 4.06 Pre. Close: 4.09
High: 4.075 Low: 3.98
Volume: 161,722 Market Cap: 308(M)

Technical analysis

as of: 2022-11-25 2:01:18 PM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 4.97     One year: 5.43
Support: Support1: 3.63    Support2: 3.02
Resistance: Resistance1: 4.26    Resistance2: 4.65
Pivot: 4.16
Moving Average: MA(5): 4.03     MA(20): 4.19
MA(100): 3.49     MA(250): 3.36
MACD: MACD(12,26): 0     Signal(9): 0.1
Stochastic oscillator: %K(14,3): 24.9     %D(3): 22.6
RSI: RSI(14): 50.3
52-week: High: 5.32  Low: 2.01
Average Vol(K): 3-Month: 773 (K)  10-Days: 740 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ VKTX ] has closed above bottom band by 19.5%. Bollinger Bands are 44.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 10 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 4.18 - 4.2 4.2 - 4.22
Low: 4.02 - 4.04 4.04 - 4.05
Close: 4.06 - 4.09 4.09 - 4.12

Company Description

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Headline News

Mon, 21 Nov 2022
15 Most Volatile Stocks to Buy Now - Yahoo Finance

Wed, 02 Nov 2022
How Will the Market React to Viking Therapeutics Inc (VKTX) Stock Getting a Bullish Rating - InvestorsObserver

Fri, 28 Oct 2022
Viking Therapeutics (NASDAQ:VKTX) has raised its price target to $11.00. - Best Stocks

Thu, 27 Oct 2022
BMRN Faces FDA In March, ALGN's Q3 Results Disappoint, VKTX Awaits VOYAGE… - Nasdaq

Tue, 18 Oct 2022
Is Viking Therapeutics Inc (VKTX) Stock a Smart Value Tuesday? - InvestorsObserver

Thu, 13 Oct 2022
Where Will Viking Therapeutics Inc (VKTX) Stock Go Next After It Has Risen 6.44% in a Week? - InvestorsObserver

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 77 (M)
Shares Float 68 (M)
% Held by Insiders 11.6 (%)
% Held by Institutions 35.7 (%)
Shares Short 1,900 (K)
Shares Short P.Month 1,880 (K)

Stock Financials

EPS -0.74
EPS Est Next Qtl -0.19
EPS Est This Year -0.83
EPS Est Next Year -0.81
Book Value (p.s.) 1.97
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -20
Return on Equity (ttm) -33.9
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0
Operating Cash Flow -50 (M)
Levered Free Cash Flow -30 (M)

Stock Valuations

PE Ratio -5.48
PEG Ratio -0.2
Price to Book value 2.03
Price to Sales 0
Price to Cash Flow -6.18

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.